Pasritamig History and Updates

13 events · 2023 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: .

0
FDA Approvals
0
Label Revisions
13
Trial Milestones
0
Pivotal Publications
Pasritamig — history and updatesFDA approvals, label revisions, recalls, trials, and pivotal publicationsFDA approvalsLabel revisionsRecalls + safetyTrialsPublications202320242025202620272028Trial: NCT07319871 2026-01-14 → 2027-01-07 (primary completion)Trial: NCT07225946 2025-12-19 → 2027-11-19 (primary completion)Trial: NCT07164443 2025-09-02 → 2028-05-30 (primary completion)Trial: NCT05818683 2023-04-26 → 2027-08-31 (primary completion)today (2026-06-08)FDA approvalLabel revisionRecall or safetyTrial activityPivotal publication

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-08Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for Pasritamig since 2023, drawn from openFDA, ClinicalTrials.gov, and PubMed.

Upcoming & expected milestones

Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT07225946
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT07164443
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT07164443
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Past events

2026
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT07319871
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
2025
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07225946
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07164443
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
2023
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT05818683
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.